TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02416739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinamide
Description: Nicotinamide (1g/day) or placebo treatment is added to the standard drug treatment (gefitinib or erlotinib) to EGFR mutated NSCLC patients

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nicotinamide
Description: Nicotinamide (1g/day) or placebo treatment is added to the standard drug treatment (gefitinib or erlotinib) to EGFR mutated NSCLC patients
Study: NCT03136016

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: educational activities
Description: Group 2 will receive classroom-based educational activities based on an earlier study, called PAPPAS, which was developed in the same city and constituted a school-based intervention with the objective of reducing the consumption of sweetened beverages and biscuits and increase the consumption of fruits, vegetables and beans

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nudging
Description: In group 3, changes in the environment will be included that will facilitate both physical activity and healthy food choices

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nudging + educational activities
Description: Group 4 will receive both interventions
Study: NCT03030118

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine is classified as an anti-malarial and it is has immunomodulatory functions that make it useful for treatment of autoimmune disorders including systemic lupus erythematosus and rheumatoid arthritis.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Description: An oral capsule placebo is made to match the active intervention medication hydroxychloroquine.
Study: NCT03643627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYNT001
Description: single IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYNT001
Description: single IV infusion
Study: NCT01572896

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Taking Charge: Managing JIA Online
Description: In addition to standard medical care, adolescents in the experimental group will receive the Taking Charge: Managing JIA Online Internet self-management program. The intervention is a 12-module interactive multi-component treatment protocol - that consists of JIA-specific education, self-management strategies, and social support - that is available in English and French.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Care and JIA Resource Center
Description: The control group is designed to control for the potential effects on outcomes of time, attention and computer use during the intervention and through the 9-month follow-up period. In addition to standard medical care, adolescents in the attention control group will be provided with access to a self-guided patient education study website, which will have two components: basic patient educational materials about JIA (JIA Resource Centre) and online assessments.
Study: NCT05401552

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Meal
Description: Comparison of two breakfast meals containing the same amount of phosphorus but one in the form of inorganic additives

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Meal
Description: Comparison of two breakfast meals containing the same amount of phosphorus but one in the form of inorganic additives
Study: NCT01171274

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hatha Yoga
Description: * 9 weeks of Hatha Yoga, designed for treating chronic neck pain, as a group intervention.~* One class of 90 minutes per week, 10 minutes training at home each day.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information regarding exercises and behaviour
Description: * 9 weeks of exercises practiced at home.~* Patients receive detailed information regarding appropriate exercises and behaviour for chronic neck pain patients.
Study: NCT03643627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYNT001
Description: single IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYNT001
Description: single IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single IV infusion
Study: NCT02309801

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Daidzin
Description: Super-Absorbable Soy Isoflavones, LifeExtension, USA. Single oral dose of 4 capsules (containing 80 mg of daidzin-daidzein).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol
Description: Alcohol single oral dose

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: Alcohol single oral dose
Study: NCT00756418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast
Description: montelukast 5 mg QD 4-weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Theophylline
Description: Theophylline 100 to 200 mg BID 4-weeks.
Study: NCT03915314

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological tests
Description: The investigators do the neuropsychological tests, Mini-Mental score examination (MMSE),Charlson Comorbidity Index(CCI)，Quality of Recovery Score - 40 (QoR-40),CAGE Alcoholism Questionnaire,blood albumin、hemoglobin content、ALT、AST、BUN、Cr、1 day before the surgery（baseline);serum biomarkers of endothelial dysfunction，blood brain barrier disruption and neuronal injury to be measured at 2 time points,1 day before the surgery（baseline）and postoperative day 1； Confusion Assessment Method（CAM)，Numerical Rating Scale（NRS）once before discharge from PACU and 1、2、3 days after surgery twice a day； QoR-40 1 day after surgery.

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological tests
Description: The investigators do the neuropsychological tests, Mini-Mental score examination (MMSE),Charlson Comorbidity Index(CCI)，Quality of Recovery Score - 40 (QoR-40),CAGE Alcoholism Questionnaire,blood albumin、hemoglobin content、ALT、AST、BUN、Cr、1 day before the surgery（baseline);serum biomarkers of endothelial dysfunction，blood brain barrier disruption and neuronal injury to be measured at 2 time points,1 day before the surgery（baseline）and postoperative day 1； Confusion Assessment Method（CAM)，Numerical Rating Scale（NRS）once before discharge from PACU and 1、2、3 days after surgery twice a day； QoR-40 1 day after surgery.
Study: NCT02488005

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: An ultrasound of the small bowel will be done by a radiologist or ultrasound technician. Subject should not eat or drink anything (i.e. no food and no water/beverages) for 8 hours prior to their ultrasound appointment
Study: NCT03811171

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Break Wave extracorporeal lithotripsy
Description: The Break Wave device will be used to exert a low amplitude burst of ultrasound waves focused at the kidney stone. The primary components of the device include an 85 mm aperture diameter therapy probe driven by a high voltage generator. The therapy probe has a cavity in the middle to accommodate coaxial alignment of an ultrasound imaging probe for treatment guidance.
Study: NCT03377153

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: hesperidin and flaxseed
Description: 2 capsuls hesperidin and 30 g flaxseed

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: no supplementation
Study: NCT03892746

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active tDCS + task oriented practice
Description: Participants in this arm will receive active tDCS(2mA) to the motor cortex(targeting the triceps) of the weaker upper limb for 2 30 minute cycles during each 2 hour upper limb training session. While receiving tDCS the participant will be performing task oriented practice for the weaker upper limb. Participants will receive these interventions for 15 sessions over several weeks up to 8 weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS + task oriented practice
Description: Participants in this arm will receive sham tDCS(0mA) to the motor cortex(targeting the triceps) of the weaker upper limb for 2 30 minute cycles during each 2 hour upper limb training session. While receiving tDCS the participant will be performing task oriented practice for the weaker upper limb. Participants will receive these interventions for 15 sessions over several weeks up to 8 weeks
Study: NCT02686437

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: TheraBand Kinesiology Tape
Description: Kinesiology taping technique is designed to target muscles and lymphatic system. Limited research is available for specific conditions, including low back pain, but it is theorized to correct muscle function by inhibiting or facilitating the muscle, improve blood flow, reduce pain, and improve joint alignment.
Study: NCT04289311

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voice Crisis Alert V2
Description: An mHealth intervention (app) with multiple components for self-management behavior development. Components include: electronic educational information, symptom monitoring and tracking, communication with a provider, health history entry and storage (including medication adherence).
Study: NCT04702841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chimeric antigen receptor modified γδ T cells
Description: Dosage: the total dosage of reinfusion is 0.2-5 × 10\^6 / kg, which is determined according to the body weight of the subject and the effective content of cell preparation.
Study: NCT03607942

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HMO supplement
Description: HMO supplement will be given three times a day, not mixed with any feeding.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Control product without any HMOs. The Placebo Comparator will be matched to the experimental product in energy content.
Study: NCT03902314

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Iv
Description: Intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: Intravenous infusion
Study: NCT01668849

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Grape extract
Description: Grape extract self-administered by mouth daily for 35 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lortab, Fentanyl patch, mouthwash
Description: Lortab 5-10 mg Fentanyl patch 25 mcgs Mary's Magic Mouthwash
Study: NCT02743013

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHF 5993 100/6/12,5 pMDI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 5993 100/6/12,5 DPI Test 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 5993 100/6/12,5 DPI Test 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHF 5993 100/6/12,5 pMDI replicate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHF 5993 100/6/12,5 pMDI with Valved Holding Chamber
Study: NCT04184297

Intervention type: DRUG
Intervention: Tiotropium and Olodaterol (Tio+Olo)
Description: drug

Intervention type: DRUG
Intervention: Long-acting beta2-agonist and Inhaled corticosteroids (LABA and ICS)
Description: drug
Study: NCT03089580

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intense Pulsed Light Therapy
Description: Intense pulsed light therapy is a non-invasive and non-laser light treatment that was approved in 1995 by the FDA for dermatology. Participants will receive a total of 4 treatments over the course of the study.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Treatment
Description: The sham treatment will mimic the IPL treatment but no light will be delivered. Sham treatment will be administered 4 times throughout the study.
Study: NCT00977626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1 - AZD2423 or Placebo
Description: AZD2423 Oral Solution, multiple dosing during 10-14 days or Placebo Oral Solution, multiple dosing during 10-14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2 - AZD2423
Description: AZD2423 Oral solution, multiple dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 3 - AZD2423
Description: AZD2423 Oral solution, single dosing or AZD2423 Oral solution, single dosing - With Food or AZD2423 Oral solution, single dosing - Fasting Condition.
Study: NCT03127293

Intervention type: DIAGNOSTIC_TEST
Intervention: DEXA
Description: Blood samples (10 mL) were drawn at the time of DEXA scans in postpartum period

Intervention type: DIAGNOSTIC_TEST
Intervention: DEXA
Description: Blood samples (10 mL) were drawn at the time of DEXA scans in postpartum period
Study: NCT02326597

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision Aid Tool
Description: The tool is a web based decision aid that provides information about the risks and benefits associated with sickle cell disease therapies. Participants will be provided a unique access ID and password to access the information.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Practice
Description: Standard of care teaching and discussion regarding treatment options given by patient's healthcare provider.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Practice
Description: Standard of care teaching and discussion regarding treatment options given by patient's healthcare provider.
Study: NCT03642652

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS
Description: Text reminders to mobile telephone
Study: NCT05937061

Intervention type: BIOLOGICAL
Intervention: Blood sample analysis
Description: Analysis of complete blood count, hemogram, serum proteins, serum iron status (iron, transferin, ferritin). Group comparison - intervention vs. control.

Intervention type: BIOLOGICAL
Intervention: Blood sample analysis
Description: Analysis of complete blood count, hemogram, serum proteins, serum iron status (iron, transferin, ferritin). Group comparison - intervention vs. control.

Intervention type: BIOLOGICAL
Intervention: Blood sample analysis
Description: Analysis of complete blood count, hemogram, serum proteins, serum iron status (iron, transferin, ferritin). Group comparison - intervention vs. control.

Intervention type: BIOLOGICAL
Intervention: Blood sample analysis
Description: Analysis of complete blood count, hemogram, serum proteins, serum iron status (iron, transferin, ferritin). Group comparison - intervention vs. control.

Intervention type: OTHER
Intervention: Anthropometrics measurement - at inclusion to the study (all groups).
Description: Measurement of body height (cm), weight (kg) and calculating BMI (kg/m2). Group comparison - intervention vs. control.

Intervention type: OTHER
Intervention: Anthropometrics measurement - at inclusion to the study (all groups).
Description: Measurement of body height (cm), weight (kg) and calculating BMI (kg/m2). Group comparison - intervention vs. control.

Intervention type: OTHER
Intervention: Anthropometrics measurement - at inclusion to the study (all groups).
Description: Measurement of body height (cm), weight (kg) and calculating BMI (kg/m2). Group comparison - intervention vs. control.

Intervention type: RADIATION
Intervention: Bone mineral density measurement (DXA)
Description: Analysis of bone mineral density with DXA in patients with milk allegy. Analysis ordered by medical doctor.
Study: NCT02686437

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TheraBand Kinesiology Tape
Description: Kinesiology taping technique is designed to target muscles and lymphatic system. Limited research is available for specific conditions, including low back pain, but it is theorized to correct muscle function by inhibiting or facilitating the muscle, improve blood flow, reduce pain, and improve joint alignment.
Study: NCT02777866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infiltration of 0.5% Bupivacaine
Description: Patients who will be non urgent operated of an open gastrointestinal surgery, where an opening of the gastrointestinal lumen occurs (bile duct, stomach, small bowel or colon), who will be infiltrated in the total thickness of the abdominal wall (Peritoneum-muscle fascia- Subcutaneous tissue) with 0.5% Bupivacaine, every 1 cm, on each side of the surgical wound

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: Infiltration of 0.9% Saline Solution
Description: Patients who will be non urgent operated of an open gastrointestinal surgery, where an opening of the gastrointestinal lumen occurs (bile duct, stomach, small bowel or colon), who will be infiltrated in the total thickness of the abdominal wall (Peritoneum-muscle fascia- Subcutaneous tissue) with 0.9% Saline Solution, every 1 cm, on each side of the surgical wound
Study: NCT03051152

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: D1 gastrectomy
Description: Gastrectomy with limited lymph node dissection
Study: NCT01147653

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Autologous UCB Reinfusion
Description: Autologous umbilical cord blood (UCB) reinfusion

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Autologous UCB Reinfusion
Description: Autologous umbilical cord blood (UCB) reinfusion

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04143451

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaxigrip tetra
Description: quadrivalent influenza vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaxigrip tetra
Description: quadrivalent influenza vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone high-dose
Description: high-dose trivalent influenza vaccine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aldara 5% Topical Cream
Description: imiquimod cream

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aqueous cream BP
Description: inactive aqueous cream

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aqueous cream BP
Description: inactive aqueous cream
Study: NCT03880721

Intervention type: PROCEDURE
Intervention: Microwave abaltion
Description: Use microwave ablation to treat hepatocellular carcinoma
Study: NCT00903981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avanafil
Description: 2 tablets(Avanafil 100mg tablet + Placebo 200mg tablet), 30 minutes before sexual intercourse

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avanafil
Description: 2 Tablets(Avanafil 200mg tablet + Placebo 100mg tablet), 30 minutes before sexual intercourse

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 Tablets(Placebo 100mg tablet + Placebo 200mg tablet), 30 minutes before sexual intercourse
Study: NCT02765984

Intervention type: DEVICE
Intervention: Transvaginal ultrasound
Description: transvaginal ultrasound done before 10 weeks gestational age measuring the distance between the lower end of the hyperechoic trophoblast ring of the gestational sac and the inner cervical os

Intervention type: DEVICE
Intervention: Transvaginal ultrasound
Description: transvaginal ultrasound done before 10 weeks gestational age measuring the distance between the lower end of the hyperechoic trophoblast ring of the gestational sac and the inner cervical os
Study: NCT03880721

Intervention type: PROCEDURE
Intervention: Microwave abaltion
Description: Use microwave ablation to treat hepatocellular carcinoma

Intervention type: PROCEDURE
Intervention: Microwave abaltion
Description: Use microwave ablation to treat hepatocellular carcinoma

Intervention type: PROCEDURE
Intervention: Microwave abaltion
Description: Use microwave ablation to treat hepatocellular carcinoma

Intervention type: PROCEDURE
Intervention: Microwave abaltion
Description: Use microwave ablation to treat hepatocellular carcinoma

Intervention type: PROCEDURE
Intervention: Microwave abaltion
Description: Use microwave ablation to treat hepatocellular carcinoma
Study: NCT01345084

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: 66- 70 Gy External, Fractions of 2.0 Gy per day, 5 days a week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: 200 mg, IV, weekly doses during the radiation therapy until completing 6 months (Diluted into 250 mL of sodium chloride sterile solution 0.9% in intravenous infusion for 30 minutes).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 75 mg/m2, IV, doses every 3 weeks (a total of three doses)
Study: NCT03302481

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: liver biopsy
Description: the biopsies will be performed under laparoscopy and taken in the lower part of the right hepatic lobe
Study: NCT01838005

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conditional cash transfer
Description: Eligible women randomized to the intervention group will receive the standard of care plus small and increasing cash payments, on the condition that they attend scheduled clinic visits on time (+/-5days), accept HIV services, deliver in a health facility, and at six weeks postpartum adhere to prescribed infant prophylactic drugs (cotrimoxazole, extended NVP) and provide blood sample for DNA PCR infant early HIV diagnosis.
Study: NCT03493490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neodolpasse
Description: Patients will receive two infusions containing 75 mg diclofenac and 30 mg orphenadrine citrate 30 minutes after fixation of the graft replacement and with a time interval of 8 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: Patients will receive two infusions containing 75 mg diclofenac 30 minutes after fixation of the graft replacement and with a time interval of 8 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive two physiologic saline infusions 30 minutes after fixation of the graft replacement and with a time interval of 8 hours.
Study: NCT02944318

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Movement Program
Description: The program duration will be one academic year (around ten months) in 2017. The intervention strategies will focus on: (1) teachers' training and activities on health in curriculum; (2) active opportunities in the school environment (facilities and materials for PA practice) and (3) health education (posters and folders to students and parents).
Study: NCT04618718

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cerebral embolic protection during TAVR
Description: The ProtEmbo system is an adjunctive device placed in the central arterial system at the beginning of a TAVR procedure to deflect embolic particles during the procedure and removed following the completion of the procedure.
Study: NCT04818359

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MoviS Training
Description: Patients will undergo a supervised exercise program consisting of 3 months of aerobic exercise training (2 d/week of directly supervised exercise and 1 d/week of remotely supervised exercise) with a progressive increase in exercise intensity (40-70% of heart rate reserve) and duration (20-60 min).